Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 2Unknown 1Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Genitourinary 3Thoracic 2Other hematologic neoplasm 2Myeloid 2Gynecologic 2Gastrointestinal 2Tumor-Agnostic 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Philadelphia Chromosome 1Neoplasm, Residual 1Leukemia 1

Interventions

fludarabine phosphate 140Cyclophosphamide 132Busulfan 102Peripheral Blood Stem Cell Transplantation 95Imatinib Mesylate 94Mycophenolic Acid 91Cytarabine 82Azacitidine 80Tacrolimus 79Cyclosporine 78Whole-Body Irradiation 77fludarabine 74Antilymphocyte Serum 71Methotrexate 65Filgrastim 63nilotinib 59Melphalan 51Decitabine 49Radiotherapy 43Dasatinib 34Granulocyte Colony-Stimulating Factor 33ruxolitinib 31Clofarabine 31Etoposide 30thymoglobulin 29Thiotepa 29Cord Blood Stem Cell Transplantation 28sargramostim 27Methylprednisolone 26Stem Cell Transplantation 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Tyrosine Kinase Inhibitors × Myeloid × Clear all
NCT05476562 2022-11-08

Study Conducted Among Patients With CML

Novartis

Completed
3,234 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01460498 2020-03-05

Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)

M.D. Anderson Cancer Center

Phase 1 Completed
3 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡